A Crossover Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and Lung Bioavailability of SUN-101 and Seebri Breezhaler Administered With and Without Activated Charcoal in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Trial Profile

A Crossover Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and Lung Bioavailability of SUN-101 and Seebri Breezhaler Administered With and Without Activated Charcoal in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Completed
Phase of Trial: Phase I

Latest Information Update: 11 May 2016

At a glance

  • Drugs Glycopyrrolate (Primary) ; Glycopyrrolate
  • Indications Chronic obstructive pulmonary disease
  • Focus Pharmacokinetics
  • Acronyms GOLDEN7
  • Sponsors Sunovion Respiratory Development
  • Most Recent Events

    • 11 May 2016 Last checked against ClinicalTrials.gov record.
    • 05 May 2016 Status changed from recruiting to completed.
    • 02 Feb 2016 Planned End Date changed from 1 Jan 2016 to 1 Apr 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top